Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects

AIMS: The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of the proposed adalimumab biosimilar MSB11022 (Merck) with Humira(®) (AbbVie), sourced from both the US (US reference product [US‐RP]) and Europe (European reference medicinal product [EU‐RMP]). METHODS: In...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Hyland, Elizabeth, Mant, Tim, Vlachos, Pantelis, Attkins, Neil, Ullmann, Martin, Roy, Sanjeev, Wagner, Volker
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5137823/
https://ncbi.nlm.nih.gov/pubmed/27285856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13039
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados